David Westenberg
Stock Analyst at Piper Sandler
(4.67)
# 175
Out of 5,123 analysts
191
Total ratings
59.26%
Success rate
27.41%
Average return
Main Sectors:
Stocks Rated by David Westenberg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ELAN Elanco Animal Health | Upgrades: Overweight | $24 → $30 | $24.31 | +23.41% | 11 | Jan 22, 2026 | |
| ZTS Zoetis | Downgrades: Neutral | $190 → $135 | $126.73 | +6.53% | 16 | Jan 22, 2026 | |
| NEOG Neogen | Reiterates: Neutral | $6.5 → $10 | $10.59 | -5.57% | 14 | Jan 12, 2026 | |
| BLLN BillionToOne | Initiates: Overweight | $150 | $85.15 | +76.16% | 1 | Dec 1, 2025 | |
| TXG 10x Genomics | Maintains: Neutral | $15 → $19 | $17.70 | +7.34% | 3 | Nov 11, 2025 | |
| TEM Tempus AI | Maintains: Neutral | $105 → $80 | $52.44 | +52.56% | 6 | Nov 11, 2025 | |
| PACB Pacific Biosciences of California | Maintains: Neutral | $1.5 → $2 | $1.72 | +16.62% | 10 | Nov 11, 2025 | |
| NTRA Natera | Maintains: Overweight | $220 → $230 | $197.08 | +16.70% | 17 | Nov 11, 2025 | |
| FLGT Fulgent Genetics | Maintains: Neutral | $21 → $30 | $23.71 | +26.53% | 10 | Nov 11, 2025 | |
| EXAS Exact Sciences | Maintains: Overweight | $70 → $80 | $102.66 | -22.07% | 13 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $7.5 | $4.50 | +66.67% | 10 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $190 → $200 | $192.30 | +4.00% | 8 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $90 | $98.36 | -8.50% | 10 | Oct 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $20 | $16.47 | +21.43% | 15 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $140 | $84.08 | +66.51% | 3 | Sep 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $510 → $700 | $643.59 | +8.76% | 11 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $11 | $11.27 | -2.40% | 10 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $190 → $185 | $133.61 | +38.46% | 16 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $260 → $280 | $278.23 | +0.64% | 4 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $28.71 | - | 2 | Jan 4, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $33.33 | - | 1 | Nov 21, 2017 |
Elanco Animal Health
Jan 22, 2026
Upgrades: Overweight
Price Target: $24 → $30
Current: $24.31
Upside: +23.41%
Zoetis
Jan 22, 2026
Downgrades: Neutral
Price Target: $190 → $135
Current: $126.73
Upside: +6.53%
Neogen
Jan 12, 2026
Reiterates: Neutral
Price Target: $6.5 → $10
Current: $10.59
Upside: -5.57%
BillionToOne
Dec 1, 2025
Initiates: Overweight
Price Target: $150
Current: $85.15
Upside: +76.16%
10x Genomics
Nov 11, 2025
Maintains: Neutral
Price Target: $15 → $19
Current: $17.70
Upside: +7.34%
Tempus AI
Nov 11, 2025
Maintains: Neutral
Price Target: $105 → $80
Current: $52.44
Upside: +52.56%
Pacific Biosciences of California
Nov 11, 2025
Maintains: Neutral
Price Target: $1.5 → $2
Current: $1.72
Upside: +16.62%
Natera
Nov 11, 2025
Maintains: Overweight
Price Target: $220 → $230
Current: $197.08
Upside: +16.70%
Fulgent Genetics
Nov 11, 2025
Maintains: Neutral
Price Target: $21 → $30
Current: $23.71
Upside: +26.53%
Exact Sciences
Nov 11, 2025
Maintains: Overweight
Price Target: $70 → $80
Current: $102.66
Upside: -22.07%
Nov 11, 2025
Maintains: Overweight
Price Target: $8 → $7.5
Current: $4.50
Upside: +66.67%
Oct 27, 2025
Maintains: Neutral
Price Target: $190 → $200
Current: $192.30
Upside: +4.00%
Oct 22, 2025
Maintains: Overweight
Price Target: $60 → $90
Current: $98.36
Upside: -8.50%
Oct 15, 2025
Maintains: Overweight
Price Target: $15 → $20
Current: $16.47
Upside: +21.43%
Sep 11, 2025
Maintains: Overweight
Price Target: $120 → $140
Current: $84.08
Upside: +66.51%
Aug 11, 2025
Maintains: Neutral
Price Target: $510 → $700
Current: $643.59
Upside: +8.76%
Aug 4, 2025
Maintains: Overweight
Price Target: $12 → $11
Current: $11.27
Upside: -2.40%
May 15, 2025
Maintains: Overweight
Price Target: $190 → $185
Current: $133.61
Upside: +38.46%
May 6, 2025
Maintains: Neutral
Price Target: $260 → $280
Current: $278.23
Upside: +0.64%
Jan 4, 2018
Upgrades: Buy
Price Target: n/a
Current: $28.71
Upside: -
Nov 21, 2017
Initiates: Neutral
Price Target: n/a
Current: $33.33
Upside: -